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Introduction
There is considerable interest in the role of iron homeostasis in pulmonary hypertension. Iron supplementation has been reported to ameliorate, and iron chelation to augment, the rise in pulmonary artery pressure seen in healthy volunteers on exposure to altitude 1, 2 . Several independent clinical centres have observed that iron deficiency without anaemia is common in patients with idiopathic pulmonary arterial hypertension (IPAH), and associated with reduced exercise capacity and survival [3] [4] [5] [6] . These data suggest that iron supplementation may be beneficial in patients with IPAH, and clinical studies are in progress to evaluate this hypothesis 7 .
Counter to this argument, studies in rats suggest that iron deficiency may protect against the development of pulmonary hypertension 8 . Both contemporaneous treatment with deferoxamine and dietary iron restriction attenuate the development of pulmonary hypertension in rats exposed to chronic hypoxia or monocrotaline, respectively 9, 10 .
We set out to understand the effect of iron deficiency in the absence of the confounding effects of another pulmonary vascular insult. Specifically, we examined the impact of iron deficiency on pulmonary haemodynamics, pulmonary vascular structure and cardiac hypertrophy over a 4-week time course. After observing striking remodelling of the pulmonary vasculature, we explored whether this may be driven by perturbation of mitochondrial biochemistry and a shift in metabolic phenotype.
We then investigated reversibility of the pulmonary vascular pathology by iron replacement and probed the potential mechanisms using targeted therapeutic interventions, the tyrosine kinase inhibitor, imatinib 11 and the metabolic modulator dichloroacetate (DCA) 12 .
Methods

Animals and experimental design
Adult male Sprague-Dawley rats (body weight 200-250g; Charles River, UK) were used. All experiments were conducted in accordance with the UK Home Office regulations. Experiments were designed as follows:
a) Iron deficient rat model -time course study: rats were divided into 4 groups (n6) and fed with either a standard diet (CTR) or an iron-deficient diet (IDD, 7mg iron/kg; TD.80396, Harlan, UK) for 2 (IDD 2WK), 3 (IDD 3WK) and 4 weeks (IDD 4WK).
b) Iron supplement treatment study: rats were divided into 3 groups (n=6) and fed with (i) a standard diet (CTR), (ii) IDD for 4 weeks (IDD 4WK), or (iii) IDD for 4 weeks plus ferric carboxymaltose treatment (IDD 4WK+Fe) (Ferinject®, iv. 75mg/Kg; twice a week for two weeks, Vifor Pharma) started after two weeks of IDD.
c) DCA and imatinib treatment study: rats were divided into 3 groups (n=6) and fed with (i)
IDD for 4 weeks (IDD 4WK), (ii) IDD for 4 weeks with DCA treatment (drinking water, 70mg/kg/day, sigma) (IDD 4WK+ DCA) and (iii) IDD with imatinib treatment (oral gavage, 100mg/kg/day, LC laboratory) (IDD 4WK+Imatinib). Treatments were initiated after two weeks of IDD and maintained for the remaining two weeks while the rats remained on the IDD. 18 FDG PET imaging study: Positron emission tomography with fluorine-18-labeled 2-fluoro-2-deoxyglucose ligand ( 18 FDG-PET) was performed in rats fed with either a standard diet (n=5) or an IDD (n=4) for 4 weeks.
d)
Haemodynamic measurements and tissue collection
Rats At the end of procedure blood was collected to obtain serum. Tissues (lung, heart, liver, skeleton muscle) were flushed with saline to clear blood and snap-frozen in liquid nitrogen, and stored at -80 
Iron markers
Hemoglobin levels (Hb) were measured by HEMOCUE reader (Sweden) and haematocrit (Hct) using a microhaemotocrite device after centrifugation and blood glucose level using a Aviva Accu-Check monitor. Circulating iron and unsaturated iron binding capacity (UIBC) were measured in plasma (Abbott Diagnostics, Ireland). Transferrin saturation (Tsat) was calculated from the iron and total iron binding capacity (TIBC). Ferritin was measured using ELISA (Alpco Diagnostics, USA). For tissue iron measurements, 0.1g of tissue was digested in 70% nitric acid, with total iron assessed by means of Inductively Coupled Plasma -Mass Spectroscopy (ICP-MS).
Histology, immunohistochemistry and immunofluorescence
Lung histology was examined by elastic Van Gieson (EVG) and haematoxylin and eosin (H&E)
staining. Peripheral vessels <50 µm diameter were counted at x40 magnification and pulmonary vascular remodelling was expressed as the proportion of vessels with double elastic lamina (>75% of the circumference) to total vessels counted. 
Real Time-PCR analysis
Total RNA was extracted by RNeasy Mini Kit (Quiagen) and reversed transcribed with M-MLV Reverse Transcriptase (Promega). Real Time PCR for GLUT1, pyruvate dehydrogenase kinase 1 (pdk1) and hexokinase 1 (hk1) was performed using pre-designed, gene-specific TaqMan primer and probe sets (Applied Biosystems). Gene expression data were normalized with the housekeeping ubc1 expression and analysis was carried out using the relative expression software tool (REST).
Mitochondrial isolation and measurement of complex I activity
Mitochondria were isolated from control or IDD rat pulmonary arteries (PA, 2 nd to 6 th division).
Briefly, freshly dissected tissues were homogenized in ice-cold isolation buffer (250 mM sucrose, 20 mM HEPES, pH 7.2, 1 mM EDTA, and 0.5% BSA) and centrifuged at 2500x g to pellet nuclear material. The supernatant was centrifuged at high-speed (9600 x g for 15 min at 4°C); the pellet was washed twice in isolation buffer by centrifugation at 9600x g. Mitochondria were frozen and stored at -80°C until use. Mitochondrial complex I activity was measured using an immunocapture enzyme activity assay according to manufacturer's instructions (Abcam).
Mitochondrial inner membranes were also isolated from mitochondria from control and IDD rat pulmonary arteries (n=3) and purified by centrifugation. Patch clamp recordings were performed to measure the mitochondrial inner membrane peak conductance levels (Supplemental material).
Cell culture
Human pulmonary artery smooth muscle cells (PASMCs) were serum-deprived and then stimulated with 50ng/ml platelet-derived growth factor (PDGF) with or without iron chelator deferoxamine 
Results
Establishment of iron deficient rat model
Rats were maintained on an IDD for up to 4 weeks and iron status evaluated (Table 1 ; Online Figure   Ia ). Both stored and circulating iron levels were reduced following 2 weeks IDD, as reflected in the significantly decreased liver (<30% of control) and serum (<20% of control) iron levels, blood ferritin and Tsat, while UIBC increased (p<0.05). This was accompanied by reduced Hb (109g/L versus 147 g/L) and Hct (38% versus 48%) in IDD rats, maintained through to 4-weeks. Lung and skeletal muscle tissue iron levels were significantly reduced over the 4 weeks (69% and 63% of control, respectively), while RV and LV tissue iron levels were reduced to 78% and 90% of control level.
Iron deficient rat develops pulmonary hypertension
IDD rats developed progressive pulmonary hypertension over the 4-week time course. Mean PAP and 
Increased HIF1α and HIF2α expressions, and STAT3 activation in the iron deficient rat lung
To better understand the molecular drivers of pulmonary vascular remodelling, we first investigated HIF1α and HIF2α levels. Iron is required for the optimal activity of prolyl hydroxylases (PHDs), which act to degrade hypoxia inducible factors 18, 19 . Western blots show an increase in both HIF1α Following up on the finding of inflammatory cells in IDD lungs, and reports that iron deficiency can cause a proinflammatory state 20 , we also measured levels of signal transducers and activators of transcription-3 (STAT3). This cytoplasmic latent transcription factor is activated by phosphorylation in response to cytokines and recently proposed to act a signalling hub in PAH 21 . Levels of phosphorylated STAT3 were increased in IDD rat lungs ( Figure 3 c-e), indicating STAT3
activation. The nuclear factor of activated T cells, NFAT, increases the transcription of multiple inflammatory mediators such as interleukins and tumor necrosis factor, and contributes directly to recruitment of inflammatory cells in remodeled vessels 22 . Increased NFAT expression was evident in the IDD rat lung with increased expression in remodelled vessels (Figure 3 f, g ).
Both STAT3 and NFAT activation have been associated with altered/suppressed mitochondrial function [22] [23] [24] , potentiating a hyperproliferative and antiapoptotic cell phenotype, and in keeping with this, we observed a 3-fold increase in the antiapoptotic regulator Bcl2 in the IDD rat lung (Online Figure IIIb) .
Iron deficiency induces alteration of mitochondrial function in vitro and in vivo
To investigate further mitochondrial activity in the presence of reduced iron, we first measured the Iron is a critical substrate for mitochondria and iron-sulfur clusters (Fe-S) exclusively formed in mitochondria are essential components of electron transport chain complexes and enzymes like succinate dehydrogenase and aconitase 24 , impacting on mitochondrial function directly. We measured mitochondrial complex I activity, the first enzyme in the mitochondrial respiratory chain, by immunocapture of NAD+ in mitochondria extracted from pulmonary arteries. In IDD rats (n=4), complex I activity was reduced compared to control animals ( Figure 4 e & f). Patch clamp measurements on mitochondrial inner membrane vesicles using a recently modified technique 25, 26 showed a drop in ion channel peak conductance levels in IDD rats (51.210.5, n=5) compared to controls (109.210.5, n=5), consistent with altered mitochondrial function (Online Figure IVa, b) .
Increased glucose uptake in the iron deficient rat lung
We reasoned that perturbation of mitochondrial function would result in a glycolytic phenotype, detectable using 18 FDG PET. Dynamic PET acquisition with kinetic analysis 14 demonstrated a significant increase in lung 18 FDG uptake in 4 week IDD animals compared to controls (Figure 5a , b compared to controls (IDD 4WK 10.5 ± 2.1; CTR 8.3 ± 0.11; mmol/L, p<0.05) (Figure 5e ), as previously observed 20, 21 .
Consistent with increased 18 FDG uptake, the remodelled pulmonary vessels demonstrated prominent GLUT1 expression by immunofluorescence (Figure 5f ). Real time PCR analysis of IDD rat lungs showed increased expression of glut1 (>2 fold) along with hk1 and pdk1 (3 and 2 fold respectively) ( Figure 5g ).
Iron supplementation treatment attenuates pulmonary hypertension in iron deficient rat
To demonstrate reversibility of the pulmonary vascular phenotype, we administered intravenous iron (Ferinject) to 2 week IDD rats 7 . Iron supplementation for 2 weeks elevated circulating iron indices and tissue iron levels and restored erythropoiesis in IDD rats to control levels ( Table 1) .
Iron treatment reduced PAP (22 ± 1.6 vs 27 ± 0.6, mmHg, p<0.05), normalised RV mass ( glucose concentration was also reduced to control levels (7.8 mmol/L ± 0.7) (Figure 6f ).
DCA and imatinib attenuate pulmonary hypertension in iron deficient rat
To examine the role of metabolic dysfunction in the development of pulmonary hypertension in IDD rats, rats with established iron deficiency were treated with DCA, an inhibitor of pyruvate dehydrogenase kinase (PDK) 11, 12 for 2 weeks while remaining on the IDD. Inhibition of PDK facilitates mitochondrial oxidative phosphorylation and has been reported to attenuate pulmonary hypertension in a number of experimental models. DCA attenuated the rise in PAP (Figure 7a ) and the associated RV hypertrophy (Figure 7b ) and pulmonary vascular remodelling (Figure 7c ; Online Figure IIa , b) seen in iron deficiency. Cardiac output was also decreased to control levels ( Figure 7d ).
An alternative strategy for probing the metabolic phenotype in our model is to treat with imatinib, a tyrosine kinase inhibitor that downregulates GLUT1. Two weeks treatment with imatinib also reduced PAP and remodelling in the presence of persistent iron deficiency (Figure 7a-d) .
Increased oncogenic protein survivin expression in iron deficient rat lung
Survivin, an inhibitor of apoptosis, is expressed in established human and experimental PAH and has been etiologically associated with the development of PAH 27 . Survivin expression was increased in the IDD rat lung and tracked pulmonary remodelling severity. Both DCA and imatinib reduced survivin expression in the lung, consistent in other animal models 28 
Discussion
We report for the first time profound vascular remodelling of pulmonary arterioles as a consequence of chronic iron deficiency in rats. The pulmonary vascular changes were associated with raised PAP, PVR and RV hypertrophy and accompanied by activation of HIF, STAT3, and mitochondrial dysfunction associated with a glycolytic phenotype. Both the hemodynamic and pulmonary vascular changes were reversed by iron replacement. Significantly, pulmonary remodelling was attenuated in the presence of persistent iron deficiency by DCA and imatinib 11, 12 , two putative investigational treatments for PAH that target aerobic glycolysis and cell proliferation, respectively.
Iron deficiency was achieved by restricting dietary iron to 7 mg/kg per day, a regimen employed by other investigators [31] [32] [33] . By two weeks, liver iron stores and serum iron and ferritin were substantially reduced (<30% of control level) and remained low. Hb and Hct were also reduced but to a lesser degree (25%). Hb remained >100g/L for the duration of the experiment, above the 70-90g/L range regarded as moderate anaemia in the rat 2 . Lung tissue iron levels were significantly reduced in IDD rats (69% of control), while RV iron levels were reduced to 78% of control level.
The pulmonary vascular remodelling observed in the IDD rats is striking and appears more severe than described in most reports of monocrotaline and hypoxia-induced pulmonary hypertension. There are notable similarities with human PAH [34] [35] [36] [37] [38] , specifically medial hypertrophy coupled with an abnormal intimal endothelium and perivascular inflammatory cell infiltration. In contrast to the pulmonary hypertension phenotype, systemic pressure and systemic vascular resistance were not affected in IDD rats. That said, cardiac output was elevated in 2 week and 4 week IDD rats (112% and 135% of control respectively), most likely in response to the reduced Hct and Hb from iron deficiency, and increased shear stress from increased pulmonary blood flow may contribute to the pulmonary vascular changes observed.
Support for a direct effect of iron deficiency on pulmonary vascular remodelling comes from the effect of iron chelation on PASMC proliferation in culture. In vivo, vascular remodelling was accompanied by increased expression of HIF1α and HIF2α protein, and downstream targets, CAIX and GLUT1, biochemical signatures of iron deficiency-induced "tissue hypoxia" 39 and integral to the pulmonary vascular remodelling observed in human IPAH and several experimental models of pulmonary hypertension [40] [41] [42] .
Inflammation is also recognised as a mediator of pulmonary vascular remodelling in many presentations of pulmonary hypertension and may participate in that associated with iron deficiency.
The relationship between inflammation and iron deficiency is complex but there is evidence that the low hepcidin levels associated with iron deficiency can cause a proinflammatory state 43 . The presence of macrophages in the IDD rat lung is relevant here, as is the activation of STAT3 and NFAT 22, 23 ; both integrate signalling from cytokines but also growth and angiogenic factors and effect actions through a number of downstream targets, including Bcl2 and survivin.
Collectively, the activated HIF, STAT3 and NFAT signalling would be expected to support a proproliferative and anti-apoptotic state. An important manifestation of this cellular phenotype is mitochondrial dysfunction, associated with a metabolic shift to glycolysis, referred to as the "Warburg effect" in oncology and postulated to play a central role in the pathogenesis of PAH 12, 14, 24 . We found that iron chelation induces hyperpolarization of the mitochondrial membrane potential and the inhibition of ROS generation in PASMCs in culture. There is also clear evidence for mitochondrial dysfunction in vivo. Mitochondria from IDD rat PAs demonstrated decreased mitochondrial complex I activity along with reduced baseline inner membrane conductance levels in comparison to control specimens. Consistent with increased expression of glut1 and the glycolysis enzymes, hk1 and pdk1, in IDD rat lungs, parenchymal 18 FDG uptake was increased, along with glycolysis as measured by dynamic PET scanning.
The pulmonary hypertension phenotype induced by iron deficiency is reversible with iron supplementation. We chose intravenous ferric carboxymaltose as it has previously been used in heart failure 44, 45 and is currently under study in a clinical trial in PAH 7 . Of greater interest, the elevated PAP and vascular remodelling were attenuated by treatment with the metabolic modulator, DCA 12 , and the anti-proliferative tyrosine kinase inhibitor, imatinib 11 , in the presence of persistent iron deficiency. DCA acts by inhibition of PDK to restore oxidative phosphorylation 46 and so reverses the metabolic shift induced by iron deficiency. Imatinib, through inhibition of PDGF, influences glucose metabolism by translocalization of GLUT1 transporters from the cell membrane into the cytosol and by inhibiting glycolysis and promoting mitochondrial oxidative glucose utilization 47 .
Our observations that iron deficiency leads to pulmonary hypertension is congruent with studies in humans that suggest iron deficiency augments the pressure response to hypoxia at altitude 3, 4 and is associated with a poor prognosis in PAH [3] [4] [5] [6] . It is at odds with two studies in rats, both of which suggest iron deficiency is protective against hypoxia-induced and monocrotaline-induced pulmonary hypertension 9, 10 . However, both these studies have confounding factors. Polycythemia is an important contributor to hypoxia-induced pulmonary hypertension; the lower haemoglobin associated with iron deficiency in that model would be expected to be beneficial, as indeed it is in Tibetans acclimatised to high altitude 48, 49 . In the case of monocrotaline, inflammation plays a major role in the genesis of the vascular lesion and iron deficiency can alter the inflammatory response. Examination of the effects of iron deficiency in the absence of hypoxia or monocrotaline provide a more potent approach to unmask the effects of tissue iron depletion alone.
An important observation is that the lung, like the liver, is susceptible to iron depletion during dietary iron deficiency, more so than the myocardium. Iron deficiency is important in heart failure and has received considerable attention in recent years 50 . Iron supplementation has been shown to improve well-being and exercise capacity in patients with left heart failure 44, 45 . It remains to be seen whether it improves survival. In this study we did not study cardiac function in detail. Both the LV and RV showed evidence of hypertrophy in the iron deficient rat. But in keeping with pulmonary hypertension, the RVH index (RV/LV+sep) was increased and responded to iron replacement, as well as treatment with DCA and imatinib. in the remodelled vessels of IDD 4WK rat; smooth muscle actin (SMA, green), GLUT-1, red;
Bar=100m. g) Levels of expression of glucose transporter 1 (glut1), pyruvate dehydrogenase kinase 1 (pdk1) and hexokinase 1 (hk1) in IDD 4WK rat lungs; data are presented as fold changed compared to controls (baseline) (n=3); fold changes were calculated using the REST software. Each group were compared to control using Student's t-test, *p<0.05. The consequent pulmonary vascular cell apoptosis resistance, hyper-proliferation and inflammatory cell infiltration contribute to the striking pulmonary vascular remodelling in the iron deficient rat.
Treatments targeted at restoring normal mitochondrial activity with an inhibitor of pyruvate dehydrogenase kinase (PDK) known to promote mitochondrial oxidative phosphorylation, dichloroacetate (DCA), and an antiproliferative tyrosine kinase inhibitor which acts to downregulate glucose transporter (GLUT1), imatinib, attenuate pulmonary hypertension and vascular remodeling in the presence of persistent chronic iron deficiency. 
What Is Known?
 Pulmonary arterial hypertension is commonly associated with iron deficiency.
 Iron deficiency, even in the absence of anaemia, is associated with a poor clinical outcome in pulmonary arterial hypertension.
What New Information Does This Article Contribute?
 Chronic dietary iron deficiency induces structural changes in the pulmonary vasculature of the rat, associated with raised pulmonary arterial pressure and right heart hypertrophy.
 The vascular changes are associated with altered mitochondrial function and bioenergetics.
 Iron deficiency may have a direct effect on pulmonary vascular homeostasis and contribute adversely to the vascular pathology of pulmonary arterial hypertension.
To address whether iron deficiency is simply a biomarker of morbidity or actively contributes to the vascular pathology of pulmonary arterial hypertension, we studied rats on a chronic iron deficient diet. Pulmonary hypertension was evident after 2 weeks and histological examination of the lungs showed striking remodelling of pulmonary arterioles, with medial hypertrophy, abnormal intimal endothelium and perivascular inflammatory cell infiltration. The pulmonary vasculature exhibited the biochemical signature of mitochondrial dysfunction, with a shift in cellular metabolism towards glycolysis. The pulmonary hypertension and vascular remodeling were attenuated in the presence of persistent chronic iron deficiency by treatments targeted at restoring normal mitochondrial activity (dichloroacetate) and inhibiting cellular proliferation (imatinib). Our observations suggest that iron availability has a direct impact on pulmonary vascular homeostasis and has implications for correcting iron deficiency in patients with pulmonary hypertension.
Supplemental Material
Electrophysiology
Mitochondrial inner membranes were isolated from control or IDD rat pulmonary arteries (n=3) and 
